Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus placebo in biologic-inadequate-response psoriatic arthritis
NL-OMON48089Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) and plaque psoriasis comparing Risankizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on NL-OMON48089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48089.